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Abstract: GPR17 is a hybrid G-protein-coupled receptor activated by two unrelated ligand families, extracellular 
nucleotides and cysteinyl-leukotrienes, and involved in brain damage and repair. Its exploitment as a target for novel 
neuroreparative strategies depends on the elucidation of the molecular determinants driving binding of its ligands. We 
applied docking and molecular dynamics simulations to analyse the binding and the forced unbinding of two GPR17 
ligands (the purinergic agonist UDP and the leukotriene receptor antagonist pranlukast) from both the wild-type receptor 
and a mutant model, where a basic residue hypothesized to be crucial for nucleotide binding had been mutated (R255I). 
Molecular dynamics suggested that GPR17 nucleotide binding pocket is enclosed between the helical bundle and EL2. 
The driving interaction involves R255 and the UDP phosphate moiety. Steered molecular dynamics experiments showed 
that the energy required to unbind UDP is higher for the wild-type receptor than for R255I. Three potential binding sites 
for pranlukast were found. In one of its preferential docking conformations, pranlukast tetrazole group is close to R255 
and phenyl rings are placed into a subpocket highly conserved among GPCRs. Pulling forces developed to break polar and 
aromatic interactions of pranlukast were comparable. No differences between the wild-type receptor and the R255I 
receptor were found for the unbinding of pranlukast. These data suggest a crucial role for R255 in binding of nucleotides 
to GPR17. Aromatic interactions are instead likely to play a predominant role in the recognition of pranlukast, suggesting 
that two different binding subsites are present on GPR17. 
Keywords: Steered molecular dynamics, GPR17, G-protein-coupled receptor, cysteinyl-leukotrienes, extracellular nucleotides, 
structural biology, homology modelling. 
INTRODUCTION 
 GPR17 is a hybrid G-protein-coupled receptor (GPCR) 
that responds two both extracellular nucleotides (UDP and 
UDP-sugars) and cysteinyl-leukotrienes (cysteinyl-LTs, such 
as LTC4, LTD4
 
and LTE4), linking thus the P2Y and the 
CysLT receptor families. Furthermore, besides endogenous 
ligands, synthetic compounds typical of the two above 
receptor families are also active at GPR17. GPR17 activation 
can be contrasted by treatment with two well known P2Y 
antagonists, MRS2179 and cangrelor, and also by the already 
marketed CysLT receptor antagonists pranlukast and 
montelukast. 
 Recently, GPR17 has been demonstrated as a new 
promising target for therapeutic neuroreparative strategies in 
either acute and chronic cerebral dysfunctions. For example, 
in a model of focal rodent brain ischemia, its in vivo early 
knock-down with either pharmacological or specific 
antisense strategies, reduces the progression of cerebral 
ischemic damage, highlighting GPR17 as novel therapeutic 
target for ischemia [1]. 
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 Since at present this diseases still remains without a 
specific pharmacological treatment, molecules active as 
GPR17 inhibitors may represent a new class of promising 
anti-ischemic agents. On the other hand, more recent data 
have shown that GPR17 indeed has a dual and 
spatiotemporal-dependent role in the development and post-
injury repair of damage in the brain and in spinal cord. 
GPR17 was also found to be activated on the adult precursor 
cells that initiate remyelination in the peri-lesioned area, 
suggesting a role in the transition between immature and 
myelinating oligodendrocytes. These data make GPR17 an 
attractive new target to foster repair not only in stroke but 
also in demyelinating diseases, such as multiple sclerosis [2-
4]. 
 Despite the fact that extracellular nucleotides and 
cysteinyl-LTs originate from totally independent metabolic 
pathways and they are known to be involved in distinct 
patho-physiological phenomena, several data suggest 
important functional interactions between the two families of 
signalling molecules and their receptors. For example, a 
cross-talk between the two families is suggested by the fact 
that both nucleotides and cysteinyl-LTs massively 
accumulate at sites of inflammation and both types of 
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receptors are co-expressed in the same peripheral 
inflammatory cells. This evidence also shows a cross-
regulated response typical of the chemoattractant systems 
[5]. Along this line, in rat brain microglial cells, both 
nucleotides and cysteinyl-LTs, that are co-released as a 
consequence of the activation of P2Y1 and CysLT receptors, 
contribute to neuroinflammation and neurodegeneration [6]. 
Nucleotides can also regulate, via heterologous 
desensitization, CysLT1 receptor activity [5] and, in parallel, 
the CysLT1 receptor antagonists pranlukast and montelukast 
can functionally influence P2Y receptor signalling pathways 
in human monocyte/macrophage-like cells [7]. In addition, 
P2Y12 was found to be promiscuously activated by both 
nucleotides and LTE4 [8], further underlying the close 
relationship between the two families. Thus, the dual 
behaviour of GPR17, may represent a bridge between the 
two receptor families and further reinforces the patho-
physiological role of their cooperation. 
 To fully understand the therapeutic potential of GPR17, 
specific ligands that do not interfere with the other P2Y or 
CysLT receptors are needed, given that the pharmacological 
profile of GPR17 overlaps with that of the already known 
P2Y and CysLT receptors. As a first step to the design of 
selective ligands, the knowledge of the structure and the 
recognition mechanism are mandatory. Along this line, we 
recently proposed a computational study of GPR17, 
highlighting a dual recognition mechanism for nucleotidic 
and leukotrienic ligands by GPR17: in fact, extracellular 
nucleotides and cysteinyl-LTs do not share the same binding 
site on GPR17. Our study, carried out on a bovine 
rhodopsin-based (bRh) model of GPR17, suggested that the 
primary nucleotide binding pocket in GPR17 is contained in 
an accessible crevice enclosed between transmembrane (TM) 
helices (mainly TM3, TM5, TM6 and TM7) and 
extracellular loop (EL) 2, in general agreement with the 
binding site proposed for small molecules to other class A 
rhodopsin-like GPCRs and for nucleotides to already known 
P2Y receptors [9]. As for P2Y receptors, within this pocket, 
the driving force for binding of nucleotides to GPR17 relies 
on the electrostatic interaction between the phosphate groups 
of incoming ligand and basic arginine residues, in particular 
the arginine at position 6.55 (R255) (Ballesteros-Weinstein 
index numbering-system, [10]). Based on our computational 
data, we also hypothesized that at the extracellular interface 
of the receptor, the N-terminus (Nt) region and EL2 and EL3 
form accessory binding surfaces that could address ligands to 
the deeper main binding pocket. We finally proposed that 
GPR17 agonists and antagonists, although they occupy the 
same TM cavity, at microscopic level they probably do not 
share the same binding pocket [11]. On the other hand, 
concerning the leukotrienic component of GPR17, the 
characterization of the binding site is even more uncertain, 
due to the flexible nature of the ligands for which the 
identification of the docked conformation to the CysLT1 and 
CysLT2 receptors has not been yet successful elucidated. 
 To get more insight into the role of residues suggested to 
be crucial for the recognition mechanism by our previous 
computational data, the basic residue R6.55 of our GPR17 
wild-type (WT) receptor model has been mutated to 
isoleucine, giving a mutant (R255I) receptor model of 
GPR17. The effects of this mutation on recognition 
nucleotides have been studied in silico, by simulating the 
“unbinding processes” of two docked ligands (the 
endogenous purinergic agonist the UDP and the leukotriene 
receptor antagonist pranlukast) from both the wild-type 
(WT) and the mutant (R255I) receptor model of GPR17. The 
results summarized in the present chapter are part of a more 
comprehensive study described in detail in reference 12. 
However, some new unpublished figures are also included. 
The comparison between the two simulations clearly showed 
that the energy required to force the unbinding of UDP from 
the WT receptor model is significantly higher than the work 
spent for the unbinding of the ligand from the R255I 
receptor. These data suggest that the same target residue 
(R255) could play a different role in either the recognition of 
distinct classes of ligands or in the modulation of receptor's 
activity when activated by ligands. The simulations 
summarized here can provide some attractive hypothesis on 
the unknown recognition mechanism and could thus be 
helpful for the planning of experimental mutagenesis studies 
and ligand affinity measurements [12]. 
COMPARISON BETWEEN GPR17 AND NEW 
TEMPLATES 
 Our MD simulations study [12] was performed on a bRh-
based homology model of GPR17, for consistency with our 
previous study on GPR17, starting from a highly refined 
structure of the receptor [11]. Nevertheless, recently, thanks 
to protein engineering, new GPCR structures have been 
solved and become available for comparative modeling: the 
adenosine A2A receptor (A2AR); the 2adrenergic receptor-
Fab (2AR-Fab) and the 2adrenergic receptor-T4 (2AR-
T4); the mutated 2adrenergic receptor-(E122W)-T4 
(2AR(E122W)-T4); the turkey 1adrenergic receptor 
(1AR) and the squid Rh [13-19]. The analysis of these 
newly published crystal GPCR structures further confirms 
that the TM7 core is conserved among the entire GPCR 
superfamily. Furthermore, between the sequences of the 
currently available GPCR structures, for GPR17 the best 
alignment score was obtained with bRh (19.3 for bRh; 15.7 
for human 2AR, 15.3 for turkey 1AR and 14.3 for human 
A2AR) that indeed still results as a good compromise for 
modeling GPR17 despite the lack on structural information 
on this receptor. To assure that the topology that we found 
for GPR17 was not an artifact due to the template, and also 
to assess if it was still reliable in view of the new GPCR 
structures, we compared our model with the structure of the 
human A2AR, the three structures of the human 2AR and the 
structure of the turkey 1AR. Superimposition of the C- 
atoms of the A2AR, the 2AR-Fab, the 2AR-T4, the 
2AR(E122W)-T4 and the 1AR to GPR17 and to bRh is 
reported in Table 1. Root mean square deviation (RMSD) 
values obtained by rigidly superimposing the three structures 
to the GPR17 model vary from 1.95 to 2.87 Å, a range which 
is not significantly different from that obtained by 
superimposition of the same structures to bRh. Globally, the 
helical pack was highly conserved among all the structures, 
and also the alignment of the -helical domains to the 
GPR17 bundle yielded a good fit, as shown in Fig. (1). 
 In spite of the overall good fit among structures, there 
were some differences in the helical rearrangement 
concerning mainly TM1. Interestingly, all the available AR 
structures reveal the presence of an unexpected -helix 
domain on the EL2, that is indeed significantly different 
The Dual Behaviour of a GPCR Involved in Brain Damage an Repair The Open Conference Proceedings Journal, 2010, Volume 1    213 
from the -hairpin organization that has been found for the 
EL2 of bRh, suggesting that this feature could be a 
requirement for the binding of reversible ligands, and that a 
different accessibility to the binding pocket could exist 
among GPCRs [20]. 
 Moreover, the A2AR structure reveals substantial 
differences in the architecture of the extracellular domains 
with respect to the other solved GPCR structures, as the EL2 
is spatially constrained by two extra disulphide bridges that 
link this loop to EL1. At this time, we don’t have any 
structural information about the macroscopic arrangement of 
EL2 and of the other extracellular loops in GPCRs but, being 
the TM bundle so well conserved during evolution, it is 
reasonable to assume that at least some of the keys for 
Table 1. Alignment Among GPR17 Model and GPCR Templates 
RMSD (Å) after alignment of -helical carbon 
Structures 
3EML 2R4R 2RH1 3D4S 2VT4 
GPR17 2.69 2.87 2.46 2.74 2.4 
bRh 1.96 2.21 2.36 2.28 2.86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Superimposition of -helical domains of the 2AR-Fab, 2AR-T4, 2AR(E122W)-T4, 1AR and A2A receptor structures to 
GPR17 model: Ribbon representation of the 2AR-Fab (2R4R), 2AR-T4 (2RH1), 2(E122W)-T4 (3D4S), 1AR (2VT4) and A2A receptor 
structures after alignment of the -helical domains to GPR17 model (in gray) are reported in cyan, orange, green, magenta and yellow 
respectively. 
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selectivity reside in the extracellular region. This feature can 
also account for the exceptional plasticity of GPCRs and 
their capability to bind such a heterogeneous spectrum of 
molecules. 
STEERED MD SIMULATIONS 
 Steered MD (SMD) experiments on GPR17-WT model, 
were set starting from the last minimized frame of the MD 
trajectory of the ligands UDP, Fig. (2), and pranlukast, Fig. 
(3), in their best docking configuration. 
 The R255 residue, that had emerged as crucial in the 
recognition mechanism, was mutated to isoleucine, obtaining 
the R255I mutant model of GPR17. SMD experiments were 
then performed in parallel for both the WT and the R255I 
mutant model complexed with the ligands; then, the 
mechanical resistance offered by the ligands through 
different unbinding pathways was measured. During the 
outgoing pathway from its pocket, the resistance yielded by 
the ligands was registered: both sterical factors and non-
bonded interactions contributed to the observed peaks of 
force in the pulling steps. Here, for the interpretation of 
results, force peaks risen from SMD trajectory have been 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Model of the best UDP conformation: GPR17-UDP complex obtained by docking and conventional MD simulation. UDP is 
displayed in yellow within the detailed binding pocket, and as spheres within the whole TM bundle. The interaction with R255 is 
highlighted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Model of the best pranlukast conformation: GPR17-pranlukast complex obtained by docking and conventional MD simulation. 
Pranlukast is displayed in orange within the detailed binding pocket and as spheres within the whole TM bundle. The interaction with R255 
is highlighted. 
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scaled to energetic values (kcal/mol). 
Forced Unbinding of UDP 
 In the configuration of the WT receptor, the basic residue 
R255 extended its sidechain across the pocket, providing the 
positive counterion needed to guide the interactions with the 
phosphate moiety typical of nucleotidic ligands, thus 
representing the driving forces for binding nucleotides. The 
architecture of the pocket of R255I-UDP complex was 
actually similar to that of the WT receptor in its starting 
configuration, but it rapidly changed during the SMD 
simulation, because it lacked the principal holder of the 
interactions network. Fig. (4) shows the SMD trajectory 
where the “extraction” of UDP from the WT and R255I 
receptor models are compared. In particular, the picture 
shows the work performed to pull out UDP from the WT (in 
red) and R255I (in black) receptor models: as expected, the 
energy required to unbind UDP from the WT receptor was 
significantly higher than that needed for the R255I receptor, 
suggesting that the mutation indeed affects the binding of 
UDP. By analyzing in detail the profile of the interactions 
occurring during our SMD simulations (data not shown), we 
found that other TM residues mainly belonging to TM3 and 
TM6, such as His252 (TM6), several tyrosines (Tyr112, 
Tyr116, Tyr120 and Tyr251) and residues belonging to 
extracellular regions (EL2, EL3 and Nt), also participated to 
the recognition of the agonist UDP. In both WT and R255I 
receptor, the EL2 plug constituted an energetic and sterical 
barrier preventing the unbinding of UDP. However, in this 
case, the overtaking of this barrier required less energy and 
took place earlier than in the WT simulation, as suggested by 
the comparison of the energetic profile of the pulling energy 
reported in Fig. (4). 
Forced Unbinding of Pranlukast 
 As mentioned before, the SMD experiments were 
performed for both the WT and the R255I model on the best 
pranlukast docking configuration. Here, the tetrazole group 
of pranlukast was close to position 6.55 on TM6, and the 
phenyl rings were embedded into the highly conserved 
aromatic/hydrophobic pocket enclosed among Phe201, 
Phe205, Phe244 and a triplet of tyrosines belonging to TM3. 
In Fig. (5), the SMD unbinding trajectory of pranlukast from 
the WT and R255I receptors are compared. 
 The picture shows the pulling energy plot, computed for 
the WT (in red) and the R255I (in black) receptor models, 
respectively. No significant differences in terms of 
maximum value of energy were found comparing the two 
energetic profile for the two models; moreover, both energy 
profiles had values significantly lower than the ones 
observed for the unbinding of UDP from the WT receptor. 
This first observation on the energy involved in the 
unbinding suggests that the mutation of Arg255 did not 
 
 
 
 
 
 
 
 
 
 
Fig. (4) Forced unbinding profile of UDP: the pulling energy developed to unbind UDP during the simulations of the forced unbinding of 
the ligand from the WT (in red) and the R255I (in black) receptor models are compared. 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Forced unbinding profile of pranlukast: the pulling energy developed to unbind pranlukast during the simulations of the forced 
unbinding of the ligand from the WT (in red) and the R255I (in black) receptor models are compared. 
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significantly affect the binding of pranlukast to its binding 
pocket. The comparison of the SMD for the WT and the 
R255I receptor model (see panel a and b, where the WT and 
the R255I simulations are reported in red and black, 
respectively), shows only one relevant energetic peak in the 
case of R255I: this happened in correspondence with the 
transition of the ligand through the plug. 
EL2 BEHAVIOR 
 Analysis of the SMD trajectory for both WT and R255I 
receptors showed that, despite the constraints imposed by the 
conserved disulphide bond Cys104-Cys181 linking EL2 to 
TM3, during the traction of the ligands out of the receptor 
EL2 moved toward the extracellular space showing an hinge 
movement that allowed the opening of the crevice on the top 
of the receptor. Measurement of the distance between the C-
 atoms of the outmost residues in both the open and closed 
forms of EL2 yielded to a maximum span of 6.6 Å, as shown 
in Fig. (6). 
 For other GPCRs, this hinge movement, that highlights 
the very high flexibility of EL2, has been already associated 
with the activation mechanism, among which the 5-HT4A the 
complement factor 5a receptor C5a, the M3 and the related 
P2Y6
 
receptors [11]. 
CONCLUSIONS 
 Here, we summarized and implemented a computational 
study of a bRh-based homology model of the human GPR17 
receptor, that extends our previous MD analysis of the 
purinergic component of this receptor and highlights some 
intriguing aspects of its dualistic nature. While our analysis 
was already in progress, the crystal structures of the first 
human GPCRs and of additional receptors from other species 
have been published [13-19]. It was therefore critical to 
verify that the basic structural assumptions previously made 
by modeling GPR17 on bRh were still true at the light of the 
new structures. To do so, we superimposed the C- atoms of 
the A2AR , the 2AR-Fab, the 2AR-T4, the 2AR(E122W)-
T4 and the 1AR to GPR17 and to bRh. The obtained RMSD 
values varied from 1.955 to 2.867 Å, a range which is not 
significantly different from that obtained by superimposition 
of the same structures to bRh. On this basis, we conclude 
that the results presented here have general value and 
actually give information on the putative 3D structure of this 
new receptor. This confirms that, in spite of their low 
sequence identity/similarity, all GPCRs share a common 
scaffold and supports the role of this approach as a powerful 
tool for the drug discovery process. However it appears 
clearly that the loops length and folding play a role in the 
ligation/recognition of the substrate. 
 Our data are also in line with some of the conclusions 
made for other GPCRs on the basis of these recently 
published crystal structures. For example, it has been 
reported that, in contrast to the -adrenergic ligands and 
retinal, the A2AR antagonist ZM241385 exhibits a 
significantly different orientation within the TM bundle. 
Interestingly, the bound A2AR ligand, while interacting with 
helices, gets also in contact with EL2 and EL3. In a similar 
way, the involvement of EL2 in ligand binding to GPR17 
was consistently predicted also by our SMD study, thus 
suggesting that this may represent a common characteristic 
of some specific GPCRs subgroups. This peculiarity adds 
diversity to the class A family of GPCRs and may play an 
important role in driving receptor selectivity. 
 Our specific challenge has been to use MD and SMD 
experiments as guide, to the design of in silico site-directed 
mutagenesis experiments that, combined with ligand affinity 
measurements and hopefully further structural information, 
will contribute to the design of new selective therapeutics for 
targeting GPR17. We focused our attention on Arg255, that 
has been proposed to play a crucial role in binding of other 
P2Y receptors to their nucleotide ligands [9], and substituted 
this Arg with Ile (R255I). Our SMD simulations showed that 
the energy required to unbind UDP was higher for the WT 
receptor model than for the mutated R255I, highlighting an 
important role for the basic residue also in GPR17 binding to 
nucleotides. No significant differences between the WT and 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). EL2 dynamical behaviour: Representative frames of the open and closed form of EL2, extracted from the SMD simulations of the 
complex GPR17-UDP, are reported in green and red,respectively. The picture shows a detailed view of the hinge movement of the loop that 
exhibits an extension up to 6.6 Å. 
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the mutated receptor were instead observed in the unbinding 
of the leukotrienic ligand pranlukast from GPR17; the 
magnitude of the forces involved was also equal to the one 
used to unbind UDP from the R255I mutant receptor. 
Furthermore, pulling forces developed to break polar and 
aromatic interactions of pranlukast were comparable, 
suggesting that aromatic interactions are likely to play a 
predominant role in the recognition of pranlukast. Compared 
with our previous data obtained simulating the forced 
unbinding of UDP, the magnitude of the energy used to 
dissociate pranlukast from both the WT and the R255I 
receptor models was also near to the one used to unbind 
UDP from the R255I mutant receptor. MD simulations thus 
suggest that the mutation of Arg255 influences the binding 
of nucleotides to GPR17, but does not affect the binding of 
pranlukast, indicating that two different subsites are present 
on GPR17 and that the intermolecular interaction networks 
with the ligands are different between UDP and pranlukast. 
This in silico data have been recently confirmed in vitro at 
the mutated R255I receptor [21]. 
 The existence of two different binding sites on GPR17, 
regardless of the agonist and antagonist nature of the ligands, 
is also consistent with the intrinsic difference in the chemical 
structure of the two classes of unrelated purinergic and 
leukotrienic ligands. Moreover, this hypothesis is also 
supported by the peculiar organization of the TM crevice, 
that, in GPR17, identifies two well defined areas with 
different hydrophilic/phobic surface profiles. At present, the 
mechanism of activation and inactivation of the receptor is 
unknown, but some general hypothesis about the most 
probable target residues can be formulated, based on the 
present computational data. Regarding the putative 
nucleotide binding site, in GPR17, in agreement with the 
other members of the P2Y receptors family, the same 
binding cavity seems to be shared by purinergic agonists and 
antagonists, at least for small ligands. As described in our 
previous work [11], the antagonist cangrelor, due to its long 
aliphatic branches that depart from the nucleobase, can reach 
regions of the protein that are inaccessible to other 
nucleotide-derived ligands. 
 Concerning the leukotrienic component of GPR17, the 
characterization of the binding site is more uncertain, due to 
the flexible nature of the ligands for which the identification 
of the docked conformation to the CysLT1 and CysLT2 
receptors has not been yet successful. Nevertheless, our data 
highlight the importance of the conserved 
aromatic/hydrophobic cluster for the recognition of 
pranlukast. Further investigations are needed to unveil 
whether this feature is shared by both agonist and 
antagonists. Finally, the hypothesis that two distinct binding 
sites, one for nucleotides and the other one leukotrienes, are 
present on GPR17 is in accordance with our previous 
experimental cross-antagonism data. It has been indeed 
demonstrated that, in 1321N1 cells heterologously 
expressing hGPR17, blockade of the cysteinyl-LT binding 
site with the CysLT antagonists montelukast or pranlukast 
did not abolish the response to uracil derivatives. In a similar 
way, blockade of the nucleotide binding site with either 
cangrelor or MRS2179 still permitted the response to LTD4. 
 With this study, we also aimed at getting some hints on 
the overall mechanism of ligand recognition, i.e. not only on 
the role of the single amino acid residues, but also on the 
role played by the conformational rearrangement and 
mobility of protein domains, such as helices and loops. In 
fact, loop regions are currently deemed to be involved in the 
binding of large molecular weight ligands (i.e., peptides), 
while their role in the recognition of small molecules-
responding GPCRs remains largely unresolved. It has been 
proposed that EL2 does not only provide a docking surface 
for the recognition mechanism, but could also act as a 
flexible “gatekeeper” in the binding of both allosteric and 
orthosteric GPCR ligands [20]. In agreement with this 
hypothesis, our SMD simulations unmasked the flexibility of 
EL2, that was not evident with conventional MD simulations 
run in the same time scale. Globally, these data advance our 
knowledge on the structure of the new hybrid receptor 
GPR17 and will eventually contribute to the design of “dual” 
ligands for this new target of high therapeutic relevance. 
METHODS 
 As highlighted above, the experiments discussed here are 
part of an already published original paper [12]. The reader 
is therefore referred to that paper for a detailed description of 
the Methods. Here, we provide a short summary of the key 
methodology mentioned in the present chapter.  
Steered Molecular Dynamics Simulations 
 A previously published rhodopsin-based homology 
model of the human GPR17 receptor embedded in a 
hydrated dipalmitoyl-phosphatidyl-choline (DPPC) bilayer 
and refined by means of conventional molecular dynamics 
(MD) was used as starting point for both the SMD studies 
[11]. 
 Docking studies and MD simulations of pranlukast and 
UDP were performed on the same stable 3D structure of 
GPR17 coming from the 10 ns MD simulations. Locally 
minimized structure of the ligands docked into the 
membrane-receptor complex subjected to conventional MD 
simulations, were used as starting points for SMD 
experiments. To induce the unbinding of ligands from the 
receptor, an external force was applied to center of mass 
(COM) of the ligand, simulating retracting cantilever 
directed along an imposed vector. Due to action reaction 
principle, the spring acts as a sensor of all interacting 
processes along the selected exit pathway. Pulling 
experiments were performed using the following parameters: 
pulling rate v = 0.004 nm/ps and constant force k = 2000 kJ/ 
mol nm2 for a total duration of 1000 ps. The vector along 
which ligands were pulled apart was imposed for both 
ligands parallel to the z axis of the protein, and also parallel 
to the principal axis of the membrane that, for a GPCR, is 
likely to correspond to the only exit path possible for a 
bound ligand. 
ABBREVIATION 
3D = three-dimensional 
bRh = bovine rhodopsin 
COM = center of mass 
DPPC = dipalmitoyl-phosphatidyl-choline 
EL = extracellular loop 
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GPCR = G-protein-coupled receptor 
LT = cysteinyl-leukotriene 
MD = molecular dynamics 
Nt = N-terminus 
SMD = steered MD 
RMSD = root mean square deviation 
TM = transmembrane 
WT = wild-type 
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